DiaSorin launches LIAISON® XL murex recHTLV-I/II assay (available outside the US and Canada only)

12/10/2012

DiaSorin announces the introduction of the new product in its portfolio, LIAISON® XL murex recHTLV-I/II assay, for the qualitative determination of antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II (anti-HTLV-I and anti-HTLV-II) in human serum or plasma samples.
The LIAISON® XL murex recHTLV-I/II is a third generation assay that  utilizes recombinant proteins and synthetic peptides able to recognize antibodies directed to both HTLV-I and HTLV-II. It is configured in a sandwich assay format and with its excellent performance, equivalent to the benchmarked assay Murex HTLV-I/II, it is an effective test for the diagnosis of HTLV-I/II infection and also for blood donor screening.
HTLV stands for Human T cell lymphotropic virus, as it infects a type of white blood cell called a T-cell or T-lymphocyte. There are two types of HTLV: HTLV-I and HTLV-II. They are retroviruses. HTLV-I it is known to cause a type of cancer, referred to as adult T-cell leukemia and lymphoma, and a demyelinating disease called HTLV-I associated myelopathy/Tropical spastic paraparesis (HAM/TSP).
It is estimated that 15-20 million people are currently infected with human T-cell lymphotropic virus type 1 (HTLV-1) worldwide. HTLV-I is endemic (common) in the Caribbean, Japan, South America, and parts of Africa. HTLV-II is found among native Americans.
Transmission of both HTLV I and II occurs through sexual contact, exposure to blood, transfusion of infected cellular blood components and perinatally, probably by breast feeding. The screening of antibodies against HTLV-I/II is an aid in the diagnosis of HTLV infection and is aimed at curbing the risk of transmitting the infection.
The new assay, that has been developed and validated for the LIAISON® XL platform, is an addition to the extensive infectious disease menu, counting already 44 assays for this clinical area, and it represents a further increasing of the menu for the blood banks, making the LIAISON® XL analyzer the best choice on a worldwide base.